CriticalOxazolidinone antibiotic×Selective 5-HT1B/1D serotonin receptor agonist
Updated · Methodology
Mechanism
Monoamine oxidase type A (MAO-A) is the main enzyme that breaks down rizatriptan (rizatriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Linezolid is an antibiotic that reversibly and non-selectively inhibits monoamine oxidase (MAO) (linezolid SmPC, AEMPS, sections 4.4 and 4.5). In a study, the selective MAO-A inhibitor moclobemide increased the mean area under the concentration curve of rizatriptan by 119% and its peak concentration by 41%, and the area under the curve of the active metabolite by more than 400% (rizatriptan label, US Food and Drug Administration, FDA, section 12.3). The Spanish rizatriptan SmPC expects a similar or greater effect with non-selective reversible MAO inhibitors such as linezolid and contraindicates the combination because of the risk of coronary artery vasoconstriction and hypertensive crises (rizatriptan SmPC, AEMPS, section 4.5). Apart from higher concentrations, triptans combined with MAO inhibitors can cause serotonin syndrome (FDA rizatriptan label, section 5.7). Serotonin syndrome, including fatal cases, has been reported when linezolid was combined with serotonergic drugs, and the US linezolid label lists triptans among these drugs (FDA linezolid label, section 5.3).
Symptoms
According to the Spanish rizatriptan summary of product characteristics (SmPC), rizatriptan combined with monoamine oxidase (MAO) inhibitors carries a risk of coronary artery vasoconstriction and hypertensive crises (rizatriptan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The US label reports rare cases of a marked rise in blood pressure with 5-HT1 agonists, rizatriptan included, sometimes reaching hypertensive crisis with acute impairment of organ systems (rizatriptan label, US Food and Drug Administration, FDA, section 5.8). Serotonin syndrome presents with mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, hyperthermia), neuromuscular signs (hyperreflexia, incoordination), nausea, vomiting and diarrhoea. It can start within minutes to hours of a new or higher dose of a serotonergic drug (FDA rizatriptan label, section 5.7). The US linezolid label adds sweating, clonus, opsoclonus, muscle rigidity, tremor and hypertonia (FDA linezolid label, section 5.3).
Management
The combination is contraindicated. The rizatriptan summary of product characteristics (SmPC) prohibits taking rizatriptan with monoamine oxidase (MAO) inhibitors or within two weeks of stopping them, and names linezolid among the non-selective reversible MAO inhibitors (rizatriptan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). According to its own SmPC, linezolid is a reversible non-selective MAO inhibitor (linezolid SmPC, AEMPS, sections 4.4 and 4.5). The US rizatriptan label contraindicates rizatriptan with MAO type A inhibitors and non-selective MAO inhibitors (rizatriptan label, US Food and Drug Administration, FDA, sections 4 and 7.5), and the US linezolid label describes linezolid as non-selective (FDA linezolid label, section 7.1). The linezolid SmPC lists triptans among the drugs it does not allow with linezolid unless close blood pressure monitoring is possible (linezolid SmPC, AEMPS, section 4.3), but the rizatriptan SmPC makes no such exception (rizatriptan SmPC, AEMPS, sections 4.3 and 4.5). Do not use rizatriptan during linezolid treatment or within two weeks of the last linezolid dose (rizatriptan SmPC, AEMPS, section 4.3). No document gives an interval for the opposite order, when linezolid is started after rizatriptan. If the two drugs have nevertheless been taken together, monitor the patient for signs of serotonin syndrome (FDA linezolid label, section 5.3). If serotonin syndrome is suspected, stop rizatriptan (FDA rizatriptan label, section 5.7). The US linezolid label advises considering whether to stop linezolid or the serotonergic drug, and starting supportive treatment (FDA linezolid label, section 5.3).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Zyvox (linezolid) prescribing information (2026)– FDA, DailyMed setid 6e70e63b-bfd5-478d-a8ee-8ba22c9efabd (Pharmacia & Upjohn), version 72, revised 06/2026, sections 4.2, 5.3, 5.9, 7.1, 7.2 and 12.3
- AEMPS: Ficha técnica: Linezolid, Zyvoxid 600 mg (nº registro 64109) (2026)– AEMPS, CIMA, nº registro 64109 (Zyvoxid 600 mg comprimidos recubiertos con película), revisión 05/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Rizatriptán (nº registro 62289), sección 4.3 (2024)– AEMPS, CIMA, nº registro 62289 (Maxalt 10 mg comprimidos, Organon Salud), revisión 07/2024, secciones 4.3, 4.4 y 4.5
- FDA: MAXALT (rizatriptan benzoate) prescribing information (2026)– FDA, DailyMed setid 007b4644-e0e7-4863-9ae3-fe09676b3f5f (Organon), revisión 01/2026 (versión 4), secciones 4, 5.2, 5.5, 5.6, 5.8 y 7.2